Menu Search
Equities

Sellas Life Sciences Group Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RXK3:MUN

Sellas Life Sciences Group Inc

Actions
  • Price (EUR)2.89
  • Today's Change-0.37 / -11.35%
  • Shares traded436.00
  • 1 Year change+97.95%
  • Beta2.2530
Data delayed at least 15 minutes, as of Feb 06 2026 08:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

  • Revenue in USD (TTM)0.00
  • Net income in USD-25.94m
  • Incorporated2006
  • Employees15.00
  • Location
    Sellas Life Sciences Group Inc7 TIMES SQUARE, SUITE 2503NEW YORK 10036United StatesUSA
  • Phone+1 (646) 200-5278
  • Fax+1 (302) 636-5454
  • Websitehttps://www.sellaslifesciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.